

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) Use of a substance or composition comprising one or more proteasome inhibitors for the manufacture of a medicament for the treatment of an individual infected with a virus selected from the group comprising varicella zoster virus, human cytomegalovirus, HHV6 and 7, Epstein-Barr virus and HHV8.
2. (Original) Use of a substance according to claim 1, wherein the individual is a human and the virus is human cytomegalovirus.
3. (Currently Amended) Use of a substance according to ~~claims one or two~~ claim 1, wherein the individual has undergone organ transplantation, is receiving immuno-suppressing chemotherapy, is otherwise immuno-suppressed, has a septic disease or has AIDS.
4. (Currently Amended) Use of a substance according to ~~any of the preceding claims~~ claim 1, wherein the proteasome inhibitor is selected from a group comprising substances which are able to block the enzymatic activity of the 26S proteasome complex and/or block enzymatic activity of the 20S proteasome core structure.
5. (Currently Amended) Use of a substance according to ~~any of the preceding claims~~ claim 1, wherein the proteasome inhibitor is selected from a group comprising:
  - a) naturally occurring proteasome inhibitors comprising:

peptide derivatives which have a C-terminal epoxy keton structure,  $\beta$ -lacton-derivatives, aclacinomycin A, lactacystin, clastolactacystein;

- b) synthetic proteasome inhibitors comprising:  
modified peptide aldehydes such as N-carbobenzoxy-L-leuciny-L-leuciny-L-leucinal (also referred to as MG132 or zLLL), or the boric acid derivative of MG232, N-carbobenzoxy-Leu-Nva-H (also referred to as MG115), N-acetyl-L-leuciny-L-leuciny-L-norleucinal (also referred to as LLnL), N-carbobenzoxy-Ile-Glu(OBut)-Ala-Leu-H (also referred to as PS-1);
- c) peptides comprising:  
an  $\alpha$ ,  $\beta$ ,-epoxyketone-structure, vinyl-sulfones such as, carbobenzoxy-L-leuciny-L-leuciny-L-leucin-vinyl-sulfon or, 4-hydroxy-5-iodo-3-nitrophenylacetyl-L-leuciny-L-leuciny-L-leucin-vinyl-sulfon (NLVS);
- d) Glyoxal- or boric acid residues such as: pyrazyl-  
CONH(CHPhe)CONH(CHisobutyl)B(OH)<sub>2</sub> and dipeptidyl-boric-acid derivatives;
- e) Pinacol-esters such as: benzyloxycarbonyl(Cbz)-Leu-leuboro-Leu-pinacol-ester.

6. (Original) Use of a substance according to claim 4 wherein the proteasome inhibitor is selected from a group comprising:

- a) epoxomicin (C<sub>28</sub>H<sub>86</sub>N<sub>4</sub>O<sub>7</sub>) and/or
- b) eponemycin (C<sub>20</sub>H<sub>36</sub>N<sub>2</sub>O<sub>5</sub>).

7. (Original) Use of substance according to claim 4, wherein the proteasome inhibitor is selected from a group comprising:

- a) PS-314 as a peptidyl-boric-acid derivative which is N-pyrazinecarbonyl-L-phenylalanin-L-leuzin- boric acid ( $C_{19}H_{25}BN_4O_4$ );
- b) PS-519 as a  $\beta$ -lacton- and a lactacystin-derivative which is 1R-[1S, 4R, 5S] -1-(1-Hydroxy-2methylpropyl)-4-propyl-6-oxa-2azabicyclo[3.2.0]heptane-3,7-dione ( $C_{12}H_{19}NO_4$ );
- c) PS-273 (morpholin-CONH-(CH-naphthyl)-CONH-(CH-isobutyl)-B(OH)<sub>2</sub>) and its enantiomere;
- d) PS-293;
- e) PS-296 (8-quinolyl-sulfonyl-CONH-(CH-napthyl)-CONH(-CH-isobutyl)-B(OH)<sub>2</sub>);
- f) PS-303 (NH<sub>2</sub>(CH-naphthyl)-CONH-(CH-isobutyl)-B(OH)<sub>2</sub>);
- g) PS-321 as (morpholin-CONH-(CH-napthyl)-CONH-(CH-phenylalanin)-B(OH)<sub>2</sub>);
- h) PS-334 (CH<sub>3</sub>-NH-(CH-naphthyl-CONH-(CH-Isobutyl)-B(OH)<sub>2</sub>);
- i) PS-325 (2-quinol-CONH-(CH-homo-phenylalanin)-CONH-(CH-isobutyl)- B(OH)<sub>2</sub>;
- j) PS-352 (phenyalanin-CH<sub>2</sub>-CH<sub>2</sub>-CONH-(CH-isobutyl)I-B(OH)<sub>2</sub>;

- k) PS-383 (pyridyl-CONH-(CH<sub>2</sub>F-phenylalanin)-CONH-(CH-isobutyl)-B(OH)<sub>2</sub>);
- l) PS-341; and
- m) PS-1 Z-Ile-Glu(O<sup>t</sup>Bu)-Ala-Leu-CHO;  
PS-2 [Benzyloxycarbonyl]-Leu-Leu-phenylalaninal or Z-LLF-CHO or Z-Leu-Leu-Phe-CHO PS-1.

8. (Original) Use of a substance according to claim 7, wherein the substance is selected from the group comprising:

- a) PS-341 and
- b) PS-1 Z-Ile-Glu(O<sup>t</sup>Bu)-Ala-Leu-CHO;  
PS-2 [Benzyloxycarbonyl]-Leu-Leu-phenylalaninal or Z-LLF-CHO or Z-Leu-Leu-Phe-CHO PS-1.
- c) PS-519 as a β-lacton- and a lactacystin-derivative which is 1R-[1S, 4R, 5S]-1-(1-Hydroxy-2methylpropyl)-4-propyl-6-oxa-2azabicyclo[3.2.0]heptane-3,7-dione (C<sub>12</sub>H<sub>19</sub>NO<sub>4</sub>)